Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

Table 1. Clinical staging of allergic bronchopulmonary aspergillosis in patients with asthma. Stage Definition Features; 0: Asymptomatic: Never diagnosed to have ABPA in the past, presentation ...

BOSTON — Symptoms improved with mepolizumab after treatment with omalizumab failed for a patient with asthma who developed allergic bronchopulmonary aspergillosis, according to a poster ...

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using ...

LEXINGTON, Mass., May 2, 2023 /PRNewswire/ -- Pulmatrix, Inc. (PULM) (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary ...

Future Microbiol. 2014;9(10):1195-1208. 0 Asymptomatic Never diagnosed to have ABPA in the past, presentation with controlled asthma (according to GINA guidelines) and meeting the diagnostic ...

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using ...

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using ...

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using ...

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using ...